Yes CRT receptors on TK tcells may dampen their e
Post# of 148174
and destroy circulating tumor cells. My cousin is the head of the breast cancer institute at MD Anderson and is involved in the study, so even if it is blinded if clinical endpoints are very different in the cohorts they can be compared the usual expected clinical outcomes, the study could halted and and un-blinded. Assuming after performing statistic multi variable, analysis the hypotheses is considered valid and could move FDA approval rapidly. I also think the EIND for the drug will be instituted with the case spike (the ICU's in Florida at full capacity)